Sapna Syngal

List of Publications by Year
in descending order

89 papers	9,167 citations	81134 38 h-index	48475 86 g-index
108 all docs	108 docs citations	108 times ranked	10437 citing authors

#	Article	IF	Citations
1	ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes. American Journal of Gastroenterology, 2015, 110, 223-262.	0.4	1,268
2	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of Clinical Oncology, 2015, 33, 3660-3667.	5.4	632
3	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.4	591
4	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	14.1	451
5	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastroenterology, 2014, 147, 502-526.	1.4	414
6	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	13.5	406
7	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	5.4	403
8	Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2014, 109, 1159-1179.	0.4	367
9	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	14.1	302
10	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1131-1153.e5.	1.4	252
11	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine, 2015, 17, 569-577.	2.4	248
12	Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology, 2015, 149, 604-613.e20.	1.4	229
13	Endoscopic Removal of Colorectal Lesionsâ€"Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 158, 1095-1129.	1.4	207
14	Prevalence and Phenotypes of APC and MUTYH Mutations in Patients With Multiple Colorectal Adenomas. JAMA - Journal of the American Medical Association, 2012, 308, 485-492.	7.0	195
15	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society TaskÂForce on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 463-485.e5.	1.0	191
16	The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History. Gastroenterology, 2011, 140, 73-81.e5.	1.4	171
17	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	2.4	166
18	Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1469.	7.0	161

#	Article	IF	Citations
19	Health Benefits and Cost-Effectiveness of Primary Genetic Screening for Lynch Syndrome in the General Population. Cancer Prevention Research, 2011, 4, 9-22.	1.6	155
20	Understanding the contribution of family history to colorectal cancer risk and its clinical implications: A stateâ€ofâ€theâ€science review. Cancer, 2016, 122, 2633-2645.	4.1	145
21	Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2165-2172.	5.4	132
22	Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 415-434.	0.4	116
23	Sharing Genetic Test Results in Lynch Syndrome: Communication With Close and Distant Relatives. Clinical Gastroenterology and Hepatology, 2008, 6, 333-338.	4.7	109
24	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	5.4	108
25	Inherited Colorectal Cancer Syndromes. Cancer Journal (Sudbury, Mass), 2011, 17, 405-415.	2.0	103
26	Endoscopic Removal of Colorectal Lesions: Recommendations by the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 435-464.	0.4	101
27	Endoscopic Removal of Colorectal Lesionsâ€”Recommendations by the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 91, 486-519.	1.0	100
28	Colorectal Cancer in Young Adults. Digestive Diseases and Sciences, 2015, 60, 722-733.	2.4	91
29	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2020, 159, 1916-1934.e2.	1.4	88
30	Recent advances in Lynch syndrome. Familial Cancer, 2019, 18, 211-219.	2.0	82
31	Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Gastroenterology, 2022, 162, 772-785.e4.	1.4	74
32	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet Oncology, The, 2021, 22, 1618-1631.	10.7	57
33	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	52
34	Comparison of the clinical prediction model PREMM_{1,2,6}and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut, 2013, 62, 272-279.	13.5	49
35	Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nature Genetics, 2019, 51, 1308-1314.	20.2	49
36	Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. New England Journal of Medicine, 2020, 383, 1028-1039.	29.7	49

#	Article	IF	Citations
37	Guidelines on genetic evaluation and management of Lynch syndrome: A consensus statement by the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2014, 80, 197-220.	1.0	48
38	Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study. Gastrointestinal Endoscopy, 2015, 82, 812-818.	1.0	44
39	Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 830-837.e1.	4.7	43
40	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 2022, 162, 2063-2085.	1.4	39
41	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2020, 92, 997-1015.e1.	1.0	38
42	Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genetics in Medicine, 2016, 18, 152-161.	2.4	36
43	A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointestinal Endoscopy, 2016, 84, 115-125.e4.	1.0	34
44	Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant. Cancer Prevention Research, 2021, 14, 215-222.	1.6	31
45	Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer, 2015, 121, 3281-3289.	4.1	30
46	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1185-1191.	1.9	30
47	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	6.3	30
48	Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2020, 115, 1751-1767.	0.4	30
49	Phenotypic Characteristics Associated With the <EMPH TYPE="ITAL">APC</EMPH> Gene I1307K Mutation in Ashkenazi Jewish Patients With Colorectal Polyps. JAMA - Journal of the American Medical Association, 2000, 284, 857.	7.0	29
50	Community Practice Implementation of a Self-administered Version of PREMM1,2,6 to Assess Risk for Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2018, 16, 49-58.	4.7	27
51	Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer. JCO Oncology Practice, 2021, 17, e236-e247.	2.7	27
52	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Follow-up After Colonoscopy and Polypectomy. Gastroenterology, 2020, 158, 1154.	1.4	25
53	Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genetics in Medicine, 2015, 17, 815-821.	2.4	21
54	Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study. Cancer Prevention Research, 2021, 14, 1021-1032.	1.6	20

#	Article	IF	Citations
55	Association of a let-7 miRNA binding region ofTGFBR1with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC). Carcinogenesis, 2016, 37, 751-758.	2.8	16
56	A Multi-Institutional Cohort of Therapy-Associated Polyposis in Childhood and Young Adulthood Cancer Survivors. Cancer Prevention Research, 2020, 13, 291-298.	1.6	16
57	Patient experiences living with pancreatic cancer risk. Hereditary Cancer in Clinical Practice, 2015, 13, 13.	1.5	14
58	A region-based gene association study combined with a leave-one-out sensitivity analysis identifies SMG1 as a pancreatic cancer susceptibility gene. PLoS Genetics, 2019, 15, e1008344.	3.3	14
59	Familial Burden and Other Clinical Factors Associated With Various Types of Cancer in Individuals With Lynch Syndrome. Gastroenterology, 2021, 161, 143-150.e4.	1.4	14
60	Therapy-Associated Polyposis as a Late Sequela of CancerÂTreatment. Clinical Gastroenterology and Hepatology, 2014, 12, 1046-1050.	4.7	13
61	Comparison of Colonoscopy Quality Measures Across Various Practice Settings and the Impact of Performance Scorecards. Digestive Diseases and Sciences, 2017, 62, 894-902.	2.4	13
62	Relationship between individual and family characteristics and psychosocial factors in persons with familial pancreatic cancer. Psycho-Oncology, 2018, 27, 1711-1718.	2.5	13
63	Surveillance of patients at high risk for colorectal cancer. Medical Clinics of North America, 2005, 89, 61-84.	2.3	12
64	Potential roles of genetic biomarkers in colorectal cancer chemoprevention. Journal of Cellular Biochemistry, 2000, 77, 28-34.	2.6	11
65	Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Familial Cancer, 2017, 16, 377-387.	2.0	11
66	Clinical Factors Associated with Urinary Tract Cancer in Individuals with Lynch Syndrome. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 193-199.	1.9	11
67	Diagnosis and Management of Cancer Risk in the Gastrointestinal Hamartomatous Polyposis Syndromes: Recommendations From the US Multi-Society Task Force on Colorectal Cancer. American Journal of Gastroenterology, 2022, 117, 846-864.	0.4	11
68	Hereditary Nonpolyposis Colorectal Cancer: A Call for Attention. Journal of Clinical Oncology, 2000, 18, 2189-2192.	5.4	9
69	Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5â„¢) for lynch syndrome risk assessment in a diverse population. Familial Cancer, 2022, 21, 167-180.	2.0	9
70	Clinical Implications of Pathogenic Germline Variants in Small Intestine Neuroendocrine Tumors (SI-NETs). JCO Precision Oncology, 2021, 5, 808-816.	3.1	9
71	Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm₅ Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing. Journal of Clinical Oncology, 2020, 38, 4086-4094.	5.4	8
72	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.8	8

#	Article	IF	Citations
73	Biallelic Mismatch Repair Deficiency: Management and Prevention of a Devastating Manifestation of the Lynch Syndrome. Gastroenterology, 2017, 152, 1254-1257.	1.4	7
74	Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointestinal Endoscopy, 2022, 95, 1025-1047.	1.0	7
75	Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Familial Cancer, 2019, 18, 317-325.	2.0	6
76	Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access. Genetics in Medicine, 2022, 24, 1196-1205.	2.4	6
77	Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment. Journal of Clinical Oncology, 2022, 40, 4083-4094.	5.4	6
78	Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals. Familial Cancer, 2021, 20, 111-116.	2.0	5
79	Health behaviours and beliefs in individuals with familial pancreatic cancer. Familial Cancer, 2019, 18, 457-464.	2.0	4
80	Spotlight: US Multi-Society Task Force on Colorectal Cancer Recommendations for Endoscopic Removal of Colorectal Lesions. Gastroenterology, 2020, 158, 1130.	1.4	4
81	ReCAP: Oncologistsâ€™ Selection of Genetic and Molecular Testing in the Evolving Landscape of Stage II Colorectal Cancer. Journal of Oncology Practice, 2016, 12, 259-260.	3.0	3
82	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.6	3
83	Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential. British Journal of Cancer, 2022, 126, 1595-1603.	6.5	3
84	Intercepting Pancreatic Cancer. Pancreas, 2018, 47, 1175-1176.	1.1	2
85	A Randomized Trial of Two Remote Health Care Delivery Models on the Uptake of Genetic Testing and Impact on Patient-Reported Psychological Outcomes in Families With Pancreatic Cancer: The Genetic Education, Risk Assessment, and Testing (GENERATE) Study. Gastroenterology, 2024, 166, 872-885.e2.	1.4	2
86	Reply to S. Raoof. Journal of Clinical Oncology, 2023, 41, 1147-1149.	5.4	1
87	Colon Cancer Screening. , 2017, , 283-296.		0
88	Reply to M.S. Daniels et al. Journal of Clinical Oncology, 2017, 35, 2588-2589.	5.4	0
89	Letter to the Editor-Recent advances in Lynch syndrome: response to MÃ¸ller et al.. Familial Cancer, 2021, 20, 121-122.	2.0	0